SG11201811272YA - Therapeutic compounds - Google Patents
Therapeutic compoundsInfo
- Publication number
- SG11201811272YA SG11201811272YA SG11201811272YA SG11201811272YA SG11201811272YA SG 11201811272Y A SG11201811272Y A SG 11201811272YA SG 11201811272Y A SG11201811272Y A SG 11201811272YA SG 11201811272Y A SG11201811272Y A SG 11201811272YA SG 11201811272Y A SG11201811272Y A SG 11201811272YA
- Authority
- SG
- Singapore
- Prior art keywords
- new
- somerset
- streets
- george
- international
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 abstract 1
- 101150022345 GAS6 gene Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 010 1111 1 0 01 OH OH OH Mil HMO 11110 1111 MI Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/222930 Al 28 December 2017 (28.12.2017) WIP0 I PCT (51) International Patent Classification: Queens, Somerset and George Streets, New Brunswick, A61K 31/496 (2006.01) C07D 241/04 (2006.01) New Jersey 08901 (US). COMOLLO, Thomas Walter C07C 233/64 (2006.01) [US/US]; Old Queens, Somerset and George Streets, New (21) International Application Number: Brunswick, New Jersey 08901 (US). KIMANI, Stanley G. PCT/US2017/037895 [US/US]; Old Queens, Somerset and George Streets, New Brunswick, New Jersey 08901 (US). (22) International Filing Date: (74) Agent: MICKELSON, John W. et al.; 7851 Metro Park- 16 June 2017 (16.06.2017) way, Suite 325, Bloomington, Minnesota 55425 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of national protection available): AE, AG, AL, AM, (30) Priority Data: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/352,499 20 June 2016 (20.06.2016) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant: RUTGERS, THE STATE UNIVERSITY HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, OF NEW JERSEY [US/US]; Old Queens, Somerset and KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, George Streets, New Brunswick, New Jersey 08901 (US). MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (72) Inventors; and OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (71) Applicants: WELSH, William J. [US/US]; Old Queens, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Somerset and George Streets, New Brunswick, New Jer- sey 08901 (US). BIRGE, Raymond [US/US]; Old Queens, (84) Designated States (unless otherwise indicated, for every = Somerset and George Streets, New Brunswick, New Jer- kind of regional protection available): ARIPO (BW, GH, sey 08901 (US). KHOLODOVYCH, Vladyslav [US/US]; GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = — Old Queens, Somerset and George Streets, New Brunswick, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, — New Jersey 08901 (US). PENG, Youyi [US/US]; Old TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — (54) Title: THERAPEUTIC COMPOUNDS — Figure 2A (57) : Certain compounds of formula I: I and salts including pharmaceutically = acceptable salts thereof are disclosed. Also disclosed are pharmaceutical compositions _ comprising a compound of formula I, processes for preparing compounds of formula = I, intermediates useful for formula I and therapeutic = = = preparing compounds of methods , TAT1 using a compound of formula I. B tn = = 0.5 = = ... * + Gas6 = 0.625 '25 2.5 5.0 Compound 11 _ (IC50 =1 15 pM) Il L' M Fe © N 'IR 2 en 0\ (I) f\"1 N N x2, IN 1-1 0 N C [Continued on next page] WO 2017/222930 Al MIDEDIMOMMIDIRMEMODEEDIEMMIHMEMOIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, SK, SM, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352499P | 2016-06-20 | 2016-06-20 | |
PCT/US2017/037895 WO2017222930A1 (en) | 2016-06-20 | 2017-06-16 | Therapeutic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811272YA true SG11201811272YA (en) | 2019-01-30 |
Family
ID=60784258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811272YA SG11201811272YA (en) | 2016-06-20 | 2017-06-16 | Therapeutic compounds |
Country Status (13)
Country | Link |
---|---|
US (1) | US10851096B2 (en) |
EP (1) | EP3471729B1 (en) |
JP (1) | JP2019526617A (en) |
KR (1) | KR20190026771A (en) |
CN (1) | CN110337293A (en) |
AU (1) | AU2017282659A1 (en) |
BR (1) | BR112018076564A2 (en) |
CA (1) | CA3028815A1 (en) |
IL (1) | IL263821A (en) |
MX (1) | MX2018015990A (en) |
RU (1) | RU2019101420A (en) |
SG (1) | SG11201811272YA (en) |
WO (1) | WO2017222930A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3700902T1 (en) | 2017-10-27 | 2023-10-30 | Boehringer Ingelheim International Gmbh | Inhibitors of trpc6 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3987179A (en) | 1975-02-14 | 1976-10-19 | Sandoz, Inc. | Isoxazolyl benzamides as pharmacological agents |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (en) | 1983-08-30 | 1985-04-24 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
WO2004019882A2 (en) | 2002-08-29 | 2004-03-11 | American Diagnostica, Inc. | METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS |
WO2004099164A1 (en) * | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection |
AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
RU2538965C2 (en) * | 2009-01-19 | 2015-01-10 | Эббви Инк. | Apoptosis inducing agents for treating cancer and immune and autoimmune diseases |
EP2580191A2 (en) * | 2010-06-10 | 2013-04-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Thioether prodrug compositions as anti-hiv and anti-retroviral agents |
-
2017
- 2017-06-16 WO PCT/US2017/037895 patent/WO2017222930A1/en unknown
- 2017-06-16 CN CN201780050929.7A patent/CN110337293A/en active Pending
- 2017-06-16 JP JP2019518174A patent/JP2019526617A/en active Pending
- 2017-06-16 BR BR112018076564-3A patent/BR112018076564A2/en not_active Application Discontinuation
- 2017-06-16 RU RU2019101420A patent/RU2019101420A/en not_active Application Discontinuation
- 2017-06-16 KR KR1020197001784A patent/KR20190026771A/en unknown
- 2017-06-16 US US16/311,136 patent/US10851096B2/en active Active
- 2017-06-16 MX MX2018015990A patent/MX2018015990A/en unknown
- 2017-06-16 AU AU2017282659A patent/AU2017282659A1/en not_active Abandoned
- 2017-06-16 SG SG11201811272YA patent/SG11201811272YA/en unknown
- 2017-06-16 CA CA3028815A patent/CA3028815A1/en not_active Abandoned
- 2017-06-16 EP EP17815972.9A patent/EP3471729B1/en active Active
-
2018
- 2018-12-19 IL IL263821A patent/IL263821A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3028815A1 (en) | 2017-12-28 |
MX2018015990A (en) | 2019-10-07 |
RU2019101420A (en) | 2020-07-21 |
JP2019526617A (en) | 2019-09-19 |
EP3471729B1 (en) | 2023-02-22 |
US20190127361A1 (en) | 2019-05-02 |
KR20190026771A (en) | 2019-03-13 |
BR112018076564A2 (en) | 2019-04-02 |
US10851096B2 (en) | 2020-12-01 |
IL263821A (en) | 2019-01-31 |
EP3471729A4 (en) | 2020-01-22 |
EP3471729A1 (en) | 2019-04-24 |
WO2017222930A1 (en) | 2017-12-28 |
CN110337293A (en) | 2019-10-15 |
AU2017282659A1 (en) | 2019-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804915RA (en) | Methods for treating huntington's disease | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201408324QA (en) | Pyridinone and pyridazinone derivatives | |
SG11201807012QA (en) | Acid addition salts of piperazine derivatives | |
CA2859619C (en) | Bromodomain inhibitors | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201810352XA (en) | New antibacterial compounds | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
SG11201402986RA (en) | Kinase inhibitors | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201908351TA (en) | Indole derivatives as efflux pump inhibitors | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201804100UA (en) | Pharmaceutical composition comprising a potent inhibitor of urat1 | |
SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib |